Cargando…
Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old m...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548572/ https://www.ncbi.nlm.nih.gov/pubmed/36226049 http://dx.doi.org/10.3389/fonc.2022.929763 |
_version_ | 1784805459567312896 |
---|---|
author | Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng |
author_facet | Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng |
author_sort | Wang, Sha-Sha |
collection | PubMed |
description | The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old man was diagnosed with advanced lung adenocarcinoma. A novel RET-MIR4299/MIR8070 fusion and RET amplification were identified using next-generation sequencing (NGS). The patient was then administered with pralsetinib. After 3 weeks of therapy, the patient had a partial response. At the time of reporting, the patient was on continuous pralsetinib. These findings broaden the range of RET fusion types and provide the basis for the hypothesis that RET intergenic fusion and amplification respond to pralsetinib treatment in lung adenocarcinoma. |
format | Online Article Text |
id | pubmed-9548572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95485722022-10-11 Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng Front Oncol Oncology The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old man was diagnosed with advanced lung adenocarcinoma. A novel RET-MIR4299/MIR8070 fusion and RET amplification were identified using next-generation sequencing (NGS). The patient was then administered with pralsetinib. After 3 weeks of therapy, the patient had a partial response. At the time of reporting, the patient was on continuous pralsetinib. These findings broaden the range of RET fusion types and provide the basis for the hypothesis that RET intergenic fusion and amplification respond to pralsetinib treatment in lung adenocarcinoma. Frontiers Media S.A. 2022-09-26 /pmc/articles/PMC9548572/ /pubmed/36226049 http://dx.doi.org/10.3389/fonc.2022.929763 Text en Copyright © 2022 Wang, Wang, Zeng, Gao, Liu, Wang, Hu and Qin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
title | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
title_full | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
title_fullStr | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
title_full_unstemmed | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
title_short | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
title_sort | case report: a novel intergenic mir4299/mir8070-ret fusion with ret amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548572/ https://www.ncbi.nlm.nih.gov/pubmed/36226049 http://dx.doi.org/10.3389/fonc.2022.929763 |
work_keys_str_mv | AT wangshasha casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT wangfang casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT zengzhen casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT gaofang casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT liuhuanhuan casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT wanghuina casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT huyi casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT qinhaifeng casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient |